Top 4 Healthcare Stocks Backed by Raymond James Analysts

Raymond James analysts identified top healthcare stocks, including Dyne Therapeutics (DYNE-251 data expected 4Q25), Ocular Therapeutix (SOL-R enrollment visibility improving), Trevi Therapeutics (Phase 2b readout in 1H25), and Tyra Biosciences (Phase 2 data in 2026). All are rated Strong Buy or Outperform.

Original reporting
Published Oct 8, 2026, 1:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$OCUL
Bullish
medium confidence
Mentioned
$OCUL · $TYRA
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OCULBullishLow
01

Why it matters

The list provides fresh analyst sentiment but no new corporate events; its primary effect is to influence short‑term positioning.

02

Market read

Analyst rankings can drive modest trading activity in the highlighted biotech stocks ahead of upcoming clinical milestones.

03

What to watch

Potential trial failures or regulatory setbacks could reverse any short‑term upside.

Relevance 4/10Novelty 3/10Timing: none

Background

Raymond James published its Current Favorites list for healthcare, selecting one buy‑rated idea per analyst.

Company-level read

Ticker impact

$OCULBullishMedium confidence
Context

Ocular Therapeutix is highlighted for its Axpaxli Phase 3 studies and upcoming 1Q26 readout.

Expected impact

potential upside as market anticipates positive trial outcomes

Evidence & confidence

Constructive view and Strong Buy rating provide short‑term buying impetus.

$TYRABullishMedium confidence
Context

Tyra Biosciences is ranked fourth for its 2026 catalysts in bladder cancer and achondroplasia trials.

Expected impact

potential upward pressure as market prices in future data milestones

Evidence & confidence

Inclusion in top‑pick list signals confidence and may attract speculative buying.

Market effects

Highlights broader biotech sector optimism around upcoming trial data.

US biotech equities may see modest gains from analyst endorsements.

Limited to investors tracking US-listed biotech stocks.

Counterpoint

Some investors may wait for actual trial results before committing, viewing the picks as speculative.

Key entities

  • Raymond James

    Equity research firm issuing the analyst rankings.

Related articles

$RKLBMed

Selling Some Rocket Lab After Launch Record

Rocket Lab (RKLB) achieved its 100th Electron launch, deploying a satellite for iQPS. Goldman Sachs raised its target price to $68. ULA's Vulcan rocket failed, destroying Amazon's (AMZN) satellites, halting launches. Analysts adjusted targets for Ondas Inc (ONDS). Peloton (PTON) launched a cheaper treadmill, the Tread Flex, aiming to boost affordability.

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.